Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.
Amarasinghe
K
K
Dalley
C
C
Dokal
I
I
Laurie
A
A
Gupta
V
V
Marsh
J
J
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D019871:Dyskeratosis Congenita / Q000150:complications* / Q000628:therapy*; D017809:Fatal Outcome; D006471:Gastrointestinal Hemorrhage; D006801:Humans; D008297:Male; D019172:Transplantation Conditioning / Q000379:methods*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D014740:Vidarabine; C024352:fludarabine